DAV132 is a product designed as a prophylactic treatment intended to prevent the development of Clostridium difficile infection, by binding with and neutralizing common antibiotics in the gut. DAV132 more generally preserves the integrity of the intestinal microbiota during antibiotic cures.It has two clinical objectives:

• Prevent the occurrence and recurrence of C. difficile infections in high risk patients receiving antibiotics such as oral and parenteral fluoroquinolones and cephalosporins;
• Decrease significantly the disruption of the intestinal microbiota for patients under antibiotic Treatment